Dimerix is GO, page-2

Just a few numbers from presentations:

FSGS drug market is estimated at $1B ANNUALLY
Diabetic Nephropathy drug market estimated at $1.5B ANNUALLY in the US (I think $2.5B annually in the world)

If we received a T/O offer of $700m, that would equate to approx. $5 per share

The potential here is staggering.

We also have Doctors on our FSGS medical advisory board that are board members of Big Pharma companies AstraZeneca and others, as well as our own directors James Williams and Hugh Alsop having fantastic success taking other drugs to commercialisation. We have fantastic phase 2A data, a reformulated 2 dose a day drug, fully cashed up for rest of phase 2 clinical trials, a small tight register. Our board have gone about this strategically, and done it fantastically well. We are very well positioned and with a market cap of <$20m, this company is the gift of a lifetime!! I would say any takeover would be much higher than the $500m VLA received and IMO, it is a not a question of if, but a question of when.